Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T17:37:14.681Z.
Calculation as of: 2026-10-06T17:37:14.681Z.
Quote observation: 2026-10-06T17:35:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 880fb47a961da82dee7b372bf013e19f9356fddf046c7e26e64914405e113cb3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Lexeo Therapeutics, Inc. Common Stock
Market Cap
$258.39M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$256.08M
Price/OCF Ratio
42.84
TTM Avg
27.05
3Y Avg
50.78
5Y Avg
58.49
Market Cap
$262.75M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$262.65M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$262.84M
Price/OCF Ratio
N/A
TTM Avg
134.67
3Y Avg
134.67
5Y Avg
134.67
Market Cap
$263.69M
Price/OCF Ratio
N/A
TTM Avg
64.10
3Y Avg
34.63
5Y Avg
150.74
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lexeo Therapeutics, Inc. Common Stock (LXEO) | $258.39M | N/A | N/A | N/A | N/A |
| AC Immune S.A. (ACIU)vs › | $256.98M | N/A | 5.20 | 5.41 | 5.41 |
| Anika Therapeutics, Inc. (ANIK)vs › | $256.08M | 42.84 | 27.05 | 50.78 | 58.49 |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $255.13M | N/A | N/A | N/A | N/A |
| Palisade Bio, Inc. (PALI)vs › | $260.37M | N/A | N/A | N/A | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $262.75M | N/A | N/A | N/A | N/A |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $262.65M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $262.84M | N/A | 134.67 | 134.67 | 134.67 |
| OraSure Technologies, Inc. (OSUR)vs › | $263.69M | N/A | 64.10 | 34.63 | 150.74 |
| Sol-Gel Technologies Ltd. (SLGL)vs › | $249.34M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
